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Nanoparticles have attracted considerable interest as cancer vaccine delivery vehicles for inducing suf-
ﬁcient CD8þ T cell-mediated immune responses to overcome the low immunogenicity of the tumor
microenvironment. Our studies described here are the ﬁrst to examine the effects of clinically-tested
human cancer-testis (CT) peptide epitopes within a synthetic nanoparticle. Speciﬁcally, we focused on
two signiﬁcant clinical CT targets, the HLA-A2 restricted epitopes of NY-ESO-1 and MAGE-A3, using a
viral-mimetic packaging strategy. Our data shows that simultaneous delivery of a NY-ESO-1 epitope
(SLLMWITQV) and CpG using the E2 subunit assembly of pyruvate dehydrogenase (E2 nanoparticle),
resulted in a 25-fold increase in speciﬁc IFN-g secretion in HLA-A2 transgenic mice. This translated to a
15-fold increase in lytic activity toward target cancer cells expressing the antigen. Immunization with a
MAGE-A3 epitope (FLWGPRALV) delivered with CpG in E2 nanoparticles yielded an increase in speciﬁc
IFN-g secretion and cell lysis by 6-fold and 9-fold, respectively. Furthermore, combined delivery of NY-
ESO-1 and MAGE-A3 antigens in E2 nanoparticles yielded an additive effect that increased lytic activity
towards cells bearing NY-ESO-1þ and MAGE-A3þ. Our investigations demonstrate that formulation of CT
antigens within a nanoparticle can signiﬁcantly enhance antigen-speciﬁc cell-mediated responses, and
the combination of the two antigens in a vaccine can preserve the increased individual responses that are
observed for each antigen alone.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Boosting a patient's immune system by immunotherapy repre-
sents a promising approach in cancer treatment [1], and cancer
vaccines in particular enable the recognition of tumor-associated
antigens for targeted destruction [2]. Although these cancer vac-
cines have been shown to elicit CD8 T cell immune responses, the
typical response levels generated are usually insufﬁcient to over-
come the low immunogenicity and immunosuppressive microen-
vironment of tumors [3,4]. For example, in a review of clinical
studies, an overall objective response rate (50% tumor sizel Engineering and Materials
wer, Irvine, CA 92697-2575,reduction) of only 2.6% was observedwith peptide vaccines derived
from gp100, MART-1, TRP-2, cancer testis NY-ESO-1, MAGE-A12, or
HER2 antigens (alone or in combination with adjuvant); these re-
sults suggest the need for development of more effective strategies
and therapies [1].
The application of nanotechnology has shown exceptional
promise towards improvement of cancer diagnosis and treatment
in recent years [5e7]. Antigen uptake by dendritic cells (DCs) de-
pends on the antigen properties such as geometry [8], surface
charge [9], and importantly, size [10,11]. Some nanoparticles have
the advantage of being in the optimal size for DCs uptake and
passive transport to the lymphatic system, with prior research
demonstrating that particles between approximately 20-45 nm are
taken up more effectively by the DCs residing in the lymph-nodes
[8,12,13]. Therefore, delivery of vaccine components with these
nanoparticles may facilitate and increase DC interaction, resulting
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One nanoparticle with favorable DC uptake properties is the E2
nanoparticle [15e17]. E2 is a 25-nm non-viral protein nanoparticle
derived from the pyruvate dehydrogenase complex of Bacillus
stearothermophilus [18]. It is composed of 60 identical monomer
subunits that self assemble into a highly thermostable dodecahe-
dral caged structure with a hollow 12-nm cavity [19], and it can be
engineered at the internal, external, and inter-subunit interfaces to
change the properties and functionality of the nanoparticle
[20e23]. Our research group has also previously demonstrated that
the viral-mimetic, simultaneous delivery of adjuvant (internally
packaged) andMHC-I restricted antigens (bound on the surface) via
E2 nanoparticles resulted in an increase in DCs activation and an-
tigen cross-presentation [16]. This was associated with a signiﬁcant
increase in antigen-speciﬁc IFN-g secretion, tumor cell lysis,
delayed B16-F10 tumor growth, and increased survival time in
C57BL/6 mice [15]. Cell uptake and biodistribution of E2 have also
been reported [17].
The target epitopes in this current study are HLA-A2 restricted
peptide sequences from New York esophageal squamous cell
carcinoma-1 (NY-ESO-1) and melanoma antigen family A, 3
(MAGE-A3) [24]. While other tumor-associated antigens (TAAs) are
often expressed at low levels in healthy tissue, expression of CTs is
restricted only to cancer cells and the immune-privileged cells in
the testis. Furthermore, CT antigens exist in a high proportion of
different human tumors such as melanoma, bladder, lung, prostate,
and breast cancers [25,26]. In particular, NY-ESO-1 is expressed in
82% of neuroblastomas and 46% melanomas [27] while MAGE-A3 is
also expressed in 76% of melanoma cancers [28]. A phase II clinical
trial of NY-ESO-1/ISCOMATRIX vaccine which was recently
completed in June 2017 (NCT00518206, ClinicalTrials.gov) resulted
in 4% partial response (based on a standard of 30% reduction in
tumor size), 48% stable disease, and 48% progressive disease; this
result highlights the generation of response to NY-ESO-1, but also
the need and potential for development of alternative strategies
that will yield more effective therapies.
Given the wide range of tumors that express CT antigens, their
relatively high level in cancer, their restricted expression, and their
potential for vaccine improvement, the CT class of antigens is an
important and signiﬁcant clinical target. In this study, we examined
the feasibility of using the E2 nanoparticle to induce cell-mediated
immune responses against NY-ESO-1 and MAGE-A3 in a mouse
model that is transgenic for the human major histocompatibility
complex, HLA-A2. While our prior work examined gp100, an anti-
gen that has mouse and human analogues, this current study fo-
cuses on antigens that are speciﬁcally expressed in humans.
We also investigate the extent of cell-mediated and cytolytic
responses by simultaneous delivery of NY-ESO-1- and MAGE-A3-
containing nanoparticles. Tumor escape after single-epitope
vaccination is common since cancers often lose expression of the
targeted antigen to evade the immune system [29]. Immunization
with combined antigens can possibly decrease the risk of tumor
escape resulting from antigen loss [30,31]. Furthermore, increasing
the number of different antigen targets in a vaccine can induce a
broader range of T cell responses simultaneously, which could be
effective in a higher number of patients. Because there is a lack of
immune-competent murine tumor models expressing these CT
antigens to examine in vivo anti-tumor efﬁcacy in the most physi-
ologically relevant way possible, we examined lytic ability ex vivo
using human cancer cell lines expressing both NY-ESO-1 and
MAGE-A3. To our knowledge, our study is the ﬁrst to test the efﬁ-
cacy of cell-mediated responses to clinically-relevant CT peptide
epitopes formulated as a nanoparticle, and it examines these hu-
man epitopes in nanoparticles both individually and in
combination.2. Methods
2.1. Materials
Reagents were purchased from Fisher Scientiﬁc unless other-
wise noted. Complete RPMI used in this study for splenocytes was
compromised of RPMI 1640 (Mediatech) with 10% heat-inactivated
FBS (Hyclone), 1 mM sodium pyruvate (Hyclone), 100 mg/ml of
streptomycin (Hyclone), 0.1 mM nonessential amino acids (Lonza),
2 mM L-glutamine (Lonza), and 100 units/ml penicillin. Cancer cell
lines used in this study were cultured in DMEM media (Sigma)
supplemented with 10% heat-inactivated FBS (Hyclone).
2.2. Peptides and CpG
CpG 1826, a bacterial DNA ligand for TLR9, was purchased from
Invivogen, and 50 benzaldehyde-modiﬁed CpG 1826 with a phos-
phorothioated backbone was synthesized by Trilink. The NY-ESO-1
and MAGE-A3 peptide epitopes were synthesized by Genscript or
Genemed Synthesis (Table 1). Peptides were synthesized both with
and without an N-terminal cysteine; the thiol on the cysteine-
modiﬁed peptides was used for conjugation to E2, whereas pep-
tides with no cysteine were used as controls. In this study, the
abbreviation (e.g., NYESO, MAGE) refers to the peptide, while the
names NY-ESO-1 and MAGE-A3 refer to the whole protein.
2.3. E2 puriﬁcation and characterization
In this study, we used the D381C mutant of the E2 nanoparticle,
which has an aspartic acid-to-cysteine mutation at position 381 in
the internal hollow cavity of the nanoparticle. The cysteine of
D381C can be used for site-directed conjugation, and this nano-
particle is abbreviated as “E2” in this study. Expression, puriﬁca-
tion, and characterization of E2 (D381Cmutant) were performed as
previously described [19]. In summary, E. coli strain BL21(DE3)
containing the E2 gene was cultured in Luria-Bertani medium
containing 100 mg/ml ampicillin. Expressionwas induced by adding
1 mM of IPTG when the culture reached the optical density of
0.6e0.9 measured at 600 nm. Cells were harvested and stored
at 80 C. Cells were lysed using a French pressure cell (Thermo
Scientiﬁc), and the insoluble fraction was removed by centrifuga-
tion. The soluble fractionwas heated at 70 C for 20min. Denatured
native E. coli protein aggregates were removed by centrifugation.
The recovered supernatant was loaded to a HiPrep Q Sepharose
anion exchange column followed by a Superose 6 size exclusion
column [19]. Purity and the molecular weight of puriﬁed E2 were
conﬁrmed with SDS-PAGE and electrospray ionization mass spec-
trometry. Dynamic light scattering and transmission electron mi-
croscopy were used to check the size, assembly, and
monodispersity of the particles. As previously described, lipopoly-
saccharide was removed using Triton X-114 (Sigma) extraction, and
endotoxin levels were evaluated using an LAL ToxinSensor kit
(Genscript) [16].
2.4. CpG and peptides conjugation
CpG 1826 modiﬁed with a 50-benzaldehyde was attached to the
TCEP-reduced cysteines in the internal cavity of E2 nanoparticles
using a N-b-maleimidopropionic acid hydrazide (BMPH) linker. The
average number of CpGmolecules conjugated to the internal cavity
of E2 nanoparticle was estimated with intensity analysis in ImageJ
software, using standardized concentrations [16]. Peptides with N-
terminal cysteines were conjugated to the native lysines on the
surface of the E2 nanoparticle by mixing the nanoparticle with a
sulfo-SMCC linker in the presence of a 10-fold excess of TCEP-
Table 1
List of peptide epitopes sequences and their respective abbreviations in this study. Conventional single-letter abbreviations for amino acids (aa) are used in the peptide epitope
sequence.
Abbreviation Antigen source Sequence Serotype Reference
NYESO NY-ESO-1 C-SLLMWITQV (aa 157e165) HLA-A2 [32] [33]
NYESO (p2) NY-ESO-1 C-ILTIRLTAA (aa 132e140) HLA-A2 [34]
MAGE MAGE-A3 C-FLWGPRALV (aa 271e279) HLA-A2 [35] [36]
MAGE (p2) MAGE-A3 C-KVAELVHFL (aa 112e120) HLA-A2 [36]
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night at 4 C. HPLC was used for peptide quantiﬁcation as previ-
ously described [15], and details are in Supplementary Materials.
2.5. Zeta potential measurements
To measure zeta potential, the diffusion barrier method with
monomodal analysis were used because they are compatible with
the amounts and physiological ionic strengths of our samples.
Malvern capillary cells were ﬁlled with buffer (50 mM potassium
phosphate at pH 7.4 with 100mMNaCl), and 150 ml of nanoparticles
(at 1.3 mg/ml) were gently injected to the bottom of the buffer-
ﬁlled capillary cells. Zeta potential was measured with a Malvern
Zetasizer (Nano ZS).
2.6. Mice
Transgenic mice expressing the human HLA-A2 gene were ob-
tained from Jackson Laboratory. All animal studies were carried out
in accordance with protocols approved by the Institute for Animal
Care and Use Committee (IACUC) at the University of California,
Irvine. Brieﬂy, 6e8 week old female HLA-A2 transgenic C57BL/6
mice were immunized subcutaneously at the base of the tail at Day
0. A priming immunizationwas followed by a booster after 14 days.
Injections were 120 ml and contained speciﬁc amounts of peptide,
E2, and CpG, based on the formulations tested. Seven days after the
last immunization, mice were sacriﬁced and spleens were isolated.
2.7. IFN-g ELISpot
For IFN-g ELISpot, we used the Ready-Set-Go kit (eBioscience).
Single-cell suspensions in RPMI were prepared from the spleens
isolated from immunized mice, and added at 5  105 and 106 cells/
well to PVDF ELISpot plates that were pre-coated with an anti-
mouse IFN-g antibody. Cells were incubated with either 10 mg/ml
of the relevant peptide or an irrelevant peptide (SIINFEKL) for
24 h at 37 C. Unstimulated cells in RPMI were plated and served as
a negative control. Positive control wells contained 2% PHA-M
(Gibco). IFN-g spots were developed following the manufacturer's
protocol. Plates were scanned and quantiﬁed using an ELISpot
reader (Cellular Technology) and immunospot analysis software
(Immunospot Analysis Pack).
2.8. Cell lines
A375, a human malignant melanoma cell line, and MCF-7, a
human breast cancer cell line, were purchased from ATCC. A375
was cultured in DMEM supplementedwith 10% FBS, andMCF-7was
cultured in DMEM supplemented with 10% FBS and 0.01 mg/ml
human recombinant insulin. Cells were incubated at 37 C, under
5% CO2, and were passaged 2e3 times a week.
2.9. Cell lysis assay
Single cell suspensions prepared from splenocytes isolated fromimmunized mice were cultured in RPMI at 5  106 cell/ml and
incubated overnight at 37 C. On day 1, 10 mg/ml of target peptide
was added to the cells, incubated for 24 h at 37 C, and washed
twice with PBS to remove the unbound peptide. On day 3, the
culture was supplemented with 0.4 ng/ml of IL-2. Peptide stimu-
lated splenocytes were collected on day 5 to perform the cytotox-
icity assay. LDH release was measured with a colorimetric assay,
CytoTox 96 (Promega), to examine the speciﬁc lysis of target cancer
cell lines expressing NY-ESO-1 and MAGE-A3 antigens. A375 ex-
presses both NY-ESO-1 [37] and MAGE-A3 [38], while MCF7 has
low expression of these antigens [39,40]. Splenocytes were counted
with a hemocytometer, co-cultured with the target cancer cell lines
at effector-to-target ratios of 100:1, 50:1, and 25:1, and evaluated
for LDH release following the manufacturer's protocol. Data is re-
ported as “% Lysis”, calculated as:
%Lysis ¼ Experimental LDH Release
Maximum LDH Release
 100
where “experimental LDH release” is the LDH release from cancer
cells co-cultured with splenocytes minus the sum of LDH release
from the cancer cells and the splenocytes cultured separately.
“Maximum LDH release” is from lysed cancer cells using the kit's
lysis buffer minus background LDH release from cancer cells.
2.10. Statistical analysis
Statistical analysis was carried out using GraphPad Prism. Data
are presented as mean ± standard error of the mean (S.E.M.) of at
least three independent experiments (n  3). Statistical analysis
was determined by a two-way ANOVA over all groups followed by a
Tukey's multiple comparison test, unless otherwise noted. P-values
less than 0.05 were considered signiﬁcant.
3. Results and discussion
3.1. Conjugation of CpG and cancer-testis peptides to E2
nanoparticle yielded intact nanoparticles
Both CpG and peptides were successfully conjugated to the E2
nanoparticle, and the results are consistent with those previously
described for conjugation of other epitopes to the E2 nanoparticle
[15,16]. The CpG-conjugated nanoparticle (CpG-E2) displayed two
distinct bands on SDS-PAGE [Fig. 1A]; the lower band at ~28 kDa is
the unconjugated E2 monomer and coincides with 28118 ± 13 Da
measured by mass spectrometry, and the band at ~35 kDa is
indicative of the conjugation of one CpG molecule attached to one
28-kDa E2 monomer. By analyzing band intensities, we estimate a
conjugation ratio of 21 ± 4 CpG molecules encapsulated per (60-
mer) protein particle, similar to prior studies [16].
Simultaneous conjugation of CpG to the internal cavity and
peptides to external surface of E2 resulted in two distinct broad
bands [Fig. 1A]. The broad band between 30 and 35 kDa shows the
heterogeneous conjugation of peptides (from Table 1) to the surface
of E2monomers (peptide-E2), and the band between 35 and 40 kDa
Fig. 1. Characterization of functionalized nanoparticles. A) SDS-PAGE shows successful conjugation of CpG and peptides (NYESO, MAGE) to E2 nanoparticles. B) DLS reveals
nanoparticle sizes of ~ 30 nm, before and after conjugation. C) TEM of CpG-NYESO-E2 nanoparticles. D) TEM of CpG-MAGE-E2 nanoparticles. Scale bars are 100 nm.
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E2 monomers (CpG-peptide-E2). We quantiﬁed the number of
peptides conjugated to the E2 nanoparticle with HPLC [15], and
found that on average, 140 ± 16 NYESO or 155 ± 21 MAGE peptides
were attached on each protein nanoparticle. Conjugation of CpG
and peptides to the E2 nanoparticle resulted in a 1:1 mass ratio.
This ratio of CpG and peptide has also been used in other studies to
successfully induce CD8 T cell responses [41,42].
Dynamic light scattering revealed a hydrodynamic diameter of
28.4± 0.7, 30± 1.3, and 30± 0.9 nm for E2, CpG-NYESO-E2, and CpG-
MAGE-E2 respectively [Fig. 1B]. DLS data conﬁrmed that particles
remained unaggregated and within the optimal reported size for
lymphatic drainage (20e45 nm) [5,12,13], even after conjugation.
This data veriﬁes that attachment of short peptides (9 amino acid
length) on the surface of the nanoparticle does not result in a dra-
matic change in size. TEM analysis further conﬁrmed intact, non-
aggregated CpG-NYESO-E2 [Fig. 1C] and CpG-MAGE-E2 [Fig. 1D]
nanoparticles. The zeta potential of E2, CpG-NYESO-E2, and CpG-
MAGE-E2 nanoparticles were 11.7 ± 1 mV, 12.8 ± 1 mV,
and 11.1 ± 1.8 mV, respectively. This data conﬁrmed that conju-
gation of NYESO or MAGE peptides on the surface and CpG inside of
the nanoparticles did not change the overall surface charge
compared to the E2 nanoparticle itself.
3.2. Immunization with CpG-NYESO-E2 nanoparticles yielded
increased antigen-speciﬁc IFN-g secretion
Different vaccine formulations of NY-ESO-1 antigen peptide,
CpG, and E2 were investigated, and ELISpot results are presented in
Fig. 2. Immunization with the CpG-NYESO-E2 nanoparticle signif-
icantly increased the NY-ESO-1 epitope-speciﬁc IFN-g secretion by
25-fold, compared to immunizationwith unbound CpG and NYESO,
at an equivalent amount of antigen and adjuvant [Fig. 2B and C]. In
contrast, we observed negligible IFN-g response by the cells pulsed
with an irrelevant SIINFEKL peptide [Fig. 2C], conﬁrming that the
response generated from immunization was speciﬁc to the NYESO
epitope. Splenocytes isolated from mice immunized with bare E2
nanoparticle also lacked signiﬁcant amounts of NYESO-speciﬁc
IFN-g secretion [Fig. 2C], conﬁrming that higher IFN-g secretion
resulting from CpG-NYESO-E2 immunization was not a result of
non-speciﬁc immune responses to the E2 delivery platform itself.
We previously observed higher DC activation towards CpG-E2
nanoparticles and also an elevated antigen cross-presentation
when a model ovalbumin peptide and CpG were delivered within
an E2 nanoparticle, relative to unbound antigen and adjuvant [16].This suggests that our observed increase in IFN-g secretion in this
experiment results from higher DCs activation and more efﬁcient
cross-presentation of the NYESO epitope. This mechanism of
improving T cell immunity by increasing DC uptake and activation
is supported by Dhodapkar et al., who observed higher antigen-
speciﬁc CD8 T cell responses with a vaccine that targeted NY-
ESO-1 antigen to the DEC205 receptor of DCs [43]. The high IFN-g
secretion speciﬁc to NYESO epitope (aa 157e165) in our study is
consistent with ELISpot/IFN-g data previously reported on a NY-
ESO-1 protein with ISCOMATRIX vaccine [44] and a lentiviral vec-
tor encoding the NY-ESO-1 gene [45]. However, in contrast to those
cases, our vaccine formulation contains only a single NY-ESO-1
epitope rather than the whole protein or gene, respectively, used
in the previous studies.
We also observed higher peptide-speciﬁc IFN-g secretion for the
group receiving immunizations of 50 mg CpG-NYESO-E2 compared
to 25 mg CpG-NYESO-E2 [Fig. 2C; groups e, f]. This demonstrates
dose dependency of the generated cell-mediated immune response
to the NYESO epitope. However, immunizationwith 100 mg of CpG-
NYESO-E2 did not increase the IFN-g secretion compared to 50 mg,
and in fact showed a signiﬁcant decrease across the cohort of mice
[Fig. S1]. This could be due to increased levels of suppressive T cells
[46], T cell exhaustion [47], or high antigen doses leading to in-
crease tolerance [48].
In addition to the NY-ESO-1 peptide epitope examined in Fig. 2
(NYESO), we examined another epitope [NYESO(p2)] (see Table 1)
that had been previously reported to yield a relatively low lysis of
NYESO(p2)-pulsed T2 cells when incubated with T lymphocytes
isolated from a patient [34]. In contrast to that study, however, our
data showed that immunization with nanoparticle formulations of
the NYESO(p2) epitope [CpG-NYESO(p2)-E2] did not result in any
signiﬁcant increase in the IFN-g secretion [Fig. S2-B]. To our
knowledge, there have been no additional reports regarding the
immunogenicity of this peptide. One explanation for this apparent
discrepancy is that the in vitro data using T2 cells [34] may not
recapitulate what happens in vivo.
3.3. Higher lysis activity toward NY-ESO-1þ cancer cells was
observed for the group immunized with CpG-NYESO-E2
nanoparticles
Lytic capacity of splenocytes isolated from immunized mice was
tested on a human melanoma cell line expressing NY-ESO-1 (A375)
[49,50] and on a human breast cancer cell line negative for NY-ESO-
1 expression (MCF-7) [39], both positive for HLA-A2 [39,49]. The
Fig. 2. ELISpot analysis of splenocytes from immunization with NY-ESO-1 formulations. A) Vaccine components per dose of different formulation groups (aef). B) Repre-
sentative ELISpot data from splenocytes of immunized group, pulsed with irrelevant peptide (SIINFEKL) or relevant epitope peptide (NYESO). C) Summary of averaged ELISpot data,
which evaluated antigen-speciﬁc IFN-g secretion. HLA-A2 mice were immunized with different formulations (aef), and splenocytes were pulsed ex vivo in the presence of relevant
peptide (NYESO) or irrelevant peptide (SIINFEKL) and analyzed for speciﬁc IFN-g secretion. Higher NY-ESO-1 epitope-speciﬁc IFN-g secretion was observed for the group that
received CpG-NYESO-E2. Data is presented as average ± S.E.M. of at least 3 independent experiments (n  3). Statistical signiﬁcance was determined by two-way ANOVA followed
by a Tukey's test (***p < 0.001; ****p < 0.0001).
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NYESO-E2 immunization [Fig. 2] translated to a 15-fold increase
in the lysis activity towards A375, compared to unbound peptide
and CpG [Fig. 3A]. In contrast, no signiﬁcant lysis was observed for
the control cell line, MCF-7 [Fig. 3A]. This data supports the spec-
iﬁcity of the immune response for the NY-ESO-1 antigen.
Our data also conﬁrms that lysis activity towards the target
cancer cell line is dose-dependent; higher activity toward A375 canFig. 3. Results of cell lysis assays using splenocytes from immunization with NY-ESO-1
mice were immunized with different formulations (a-f; see Fig. 2A for schematic), and splen
mice immunized with CpG-NYESO-E2 nanoparticles enhanced lysis activity toward A375, rel
A2 mice were immunized with different formulations (groups e, f ), and splenocytes were pu
CpG-NYESO-E2 nanoparticles immunization is dose dependent. Data is presented as average
by two-way ANOVA followed by a Tukey's test (***p < 0.001; ****p < 0.0001).be achieved by increasing the effector-to-target ratio [Fig. 3B],
where the effector cells are the splenocytes isolated from the
immunized mice and the target cells are the cancer cells. Our lysis
data is comparable to those previously reported on the NY-ESO-1/
ISCOMATRIX vaccine by which the entire NY-ESO-1 protein was
delivered [44]. Remarkably, we observed almost the same extent of
lysis by delivering a single NY-ESO-1 epitope rather than the whole
antigen with multiple epitopes, albeit toward a different target cellformulations. A) Summary of average lysis data at 100:1 effector:target ratio. HLA-A2
ocytes were pulsed ex vivo in the presence of NYESO peptide. Splenocytes isolated from
ative to free peptide and CpG. B) Cell lysis results at different effector:target ratios. HLA-
lsed ex vivo in the presence of NYESO peptide. Lytic ability toward A375 resulting from
± S.E.M. of at least 3 independent experiments. Statistical signiﬁcance was determined
Fig. 4. ELISpot analysis of splenocytes from immunization with MAGE-A3 formu-
lations. A) Vaccine components per dose of different formulation groups (aee). B)
Summary of averaged ELISpot data, which evaluated antigen-speciﬁc IFN-g secretion.
HLA-A2 mice were immunized with different formulations (aee), and splenocytes
were pulsed ex vivo in the presence of relevant peptide (MAGE) or irrelevant peptide
(SIINFEKL) and analyzed for speciﬁc IFN-g secretion. Higher MAGE-A3 epitope-speciﬁc
IFN-g secretion was observed for the group that received CpG-MAGE-E2. Data is pre-
sented as average ± S.E.M. of at least 3 independent experiments. Statistical signiﬁ-
cance was determined by two-way ANOVA followed by a Tukey's test (**p < 0.01;
***p < 0.001).
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Splenocytes isolated from mice immunized with bare E2
nanoparticles or antigen/CpG alone did not increase speciﬁc lysis
[Fig. 3A]; this conﬁrms that the signiﬁcant increase in lysis resulting
from the CpG-NYESO-E2 immunization is due to the complete
nanoparticle-adjuvant-antigen delivery system, and not the effect
of E2 or antigen alone. The E2 data is consistent with prior work by
Perham and De Berardinis, which previously demonstrated a
negligible lysis activity towards the mouse lymphoma RMA-S cell
line by splenocytes isolated from mice immunized with bare E2
nanoparticle [51]. Taken together, our data show that conjugation
of the NY-ESO-1 epitope and CpG adjuvant to the nanoparticle is an
effective delivery strategy for increasing INF-g response, and itFig. 5. Results of cell lysis assays using splenocytes from immunization with MAGE-A3
mice were immunized with different formulations (a-e; see Fig. 4A for schematic), and sple
immunized with CpG-MAGE-E2 nanoparticles enhanced lysis activity toward A375, relative
mice were immunized with different formulations (groups d,e), and splenocytes were pulsed
MAGE-E2 nanoparticles immunization is dose dependent. Data is presented as average ± S.
two-way ANOVA followed by a Tukey's test (***p < 0.001, ****p < 0.0001).results in a functional lysis activity that is speciﬁc towards the NY-
ESO-1 epitope.3.4. Immunization with CpG-MAGE-E2 nanoparticles yielded
increased antigen speciﬁc IFN-g secretion
Peptide epitopes for MAGE-A3 were conjugated to the E2
nanoparticle bearing the CpG adjuvant. The ELISpot results of im-
munizations with the different MAGE formulations are presented
in Fig. 4. Vaccination with the CpG-MAGE-E2 nanoparticles
increased the number of IFN-g spots, relative to free CpG andMAGE
[Fig. 4B]. We also observed a dose-dependent response, where
signiﬁcantly higher IFN-g secretion was obtained for mice immu-
nized with 50 mg compared to the 25 mg dose. Statistical analyses
show that IFN-g levels resulting from the irrelevant SIINFEKL
control peptide for mice immunized with 50 mg CpG-MAGE-E2
(group e) is not signiﬁcantly different compared to the other vac-
cine formulations in Fig. 4B. Similar to CpG-NYESO-E2, CpG-MAGE-
E2 increased the speciﬁc IFN-g secretion compared to the free
peptide/CpG control group, but to a lower extent (6-fold for MAGE
vs. 25-fold for NYESO for the comparable 50 mg dose). High IFN-g
secretion to this MAGE epitope was also observed in a previous
study, where HLA-A2 mice were immunized with DNA vaccine
encoding 5 epitopes, followed by a booster of peptide epitopes in
solution plus a hepatitis B virus core containing a T helper peptide
[35]. In contrast to the previous study, however, we obtained high
IFN-g secretion to the MAGE epitope without a need for T helper
peptides or a separate DNA vaccine.
The second MAGE-A3 epitope in this study, MAGE (p2), did not
affect the splenocyte IFN-g secretion when conjugated to E2-CpG
compared to unbound peptide and CpG [Fig. S2-C]. The apparent
discrepancy between our study compared to a previous investiga-
tion [52] could be due to the different experimental conditions. In
the prior study, much higher doses of peptide MAGE (p2) was used
(200 mg total) compared to ours (10 mg total), together with an
additional 120 mg of hepatitis B virus core containing a T helper
epitope [52].3.5. Higher lysis activity toward MAGE-A3þ cancer cells was
observed for the group immunized with CpG-MAGE-E2
nanoparticles
MAGE-speciﬁc lytic activity of splenocytes isolated fromformulations. A) Summary of average lysis data at 100:1 effector:target ratio. HLA-A2
nocytes were pulsed ex vivo in the presence of MAGE. Splenocytes isolated from mice
to free peptide and CpG. B) Cell lysis results at different effector:target ratios. HLA-A2
ex vivo in the presence of MAGE peptide. Lytic ability toward A375 resulting from CpG-
E.M. of at least 3 independent experiments. Statistical signiﬁcance was determined by
M. Neek et al. / Biomaterials 156 (2018) 194e203200immunized mice was tested using A375 and MCF-7, which are
positive [38,53] and negative [40] for MAGE-A3, respectively, and
results are presented in Fig. 5. Splenocytes isolated from mice
immunized with CpG-MAGE-E2 nanoparticles signiﬁcantly
enhanced the lytic activity toward A375 by 9-fold at a 100:1
effector-to-target ratio [Fig. 5A], compared to free peptide and CpG.
As expected, lytic activity observed for the mice immunized with
CpG-MAGE-E2 is speciﬁc to the cell line expressing MAGE, where
no signiﬁcant lysis was observed for the control cell line MCF-7. As
with the results for the NY-ESO-1 antigen on our nanoparticle, our
data conﬁrms dose dependency of lysis activity toward target cell
line [Fig. 5B]. Our data is also consistent with results previously
reporting that the MAGE-speciﬁc CD8 T cells generated fromFig. 6. Cell-mediated immune responses using splenocytes from co-immunization with
formulation groups (aef). B) Summary of averaged ELISpot data, which evaluated antigen-sp
Splenocytes of immunized mice were pulsed ex vivo in the presence of relevant peptide (NYE
Data is presented as average ± S.E.M. of at least 3 independent experiments. Statistical signiﬁ
***p < 0.001). C) Summary of average lysis activity at 100:1 effector: target ratio. Mice recei
with target cells (A375 or MCF-7). Co-immunization with CpG-NYESO-E2 and CpG-MAGE-E2
cell line (A375), relative to immunization with one antigen. Data is presented as average ± S
two-way ANOVA followed by a Tukey's test (**p < 0.01; ***p < 0.001). D) Cell lysis results at
(groups b,d) and combined (group f) antigens when bound to E2 and CpG.immunization of MAGE epitope within bacteriophage are capable
of recognizing and lysis of the MAGE-A3þ cell line [54]. Our data for
the MAGE epitope, together with the data generated for the NYESO
epitope, conﬁrm that the E2 nanoparticle can be used as an effec-
tive platform to simultaneously deliver clinically-tested CT antigens
and CpG, resulting in an increase in the cellular-mediated immune
responses generated to the target epitope.3.6. Co-immunization with nanoparticles bearing both NYESO and
MAGE epitopes yielded an additive IFN-g effect and increased the
lysis activity
Prior studies have demonstrated that targeting a tumor throughNY-ESO-1 and MAGE-A3 formulations. A) Vaccine components per dose of different
eciﬁc IFN-g secretion. HLA-A2 mice were immunized with different formulations (aef).
SO or MAGE) or irrelevant peptide (SIINFEKL) and analyzed for speciﬁc IFN-g secretion.
cance was determined by two-way ANOVA followed by a Bonferroni's test (**p < 0.01;
ved immunizations with different formulations (aef), and splenocytes were incubated
nanoparticles signiﬁcantly enhanced the lytic activity toward HLA-A2þ and MAGE-A3þ
.E.M. of at least 3 independent experiments. Statistical signiﬁcance was determined by
different effector:target ratios. Data show dose-dependent cell lysis for both individual
M. Neek et al. / Biomaterials 156 (2018) 194e203 201multiple antigen sources can decrease the possibility of tumor
escape. For example, Banchereau et al. demonstrated clinical
beneﬁt for patients who received vaccines composed of four
different melanoma antigens if at least two out of four antigen
peptides were immunogenic in patients, rather than one peptide
alone [55,56]. Similar observations have been made for renal cell
cancer [57]. Therefore, we investigated the effects of simultaneous
immunization with CpG-NYESO-E2 and CpG-MAGE-E2
nanoparticles.
We observed that immunization with the CpG-NYESO-E2 and
CpG-MAGE-E2 nanoparticles together (25 mg each, 50 mg total per
dose) signiﬁcantly increased the NYESO andMAGE epitope-speciﬁc
IFN-g secretion, compared to immunization with simultaneous
vaccination of unbound CpG, NYESO, and MAGE peptides [Fig. 6B].
As expected, we observed negligible IFN-g for the cells pulsed with
an irrelevant SIINFEKL peptide [Fig. 6B], conﬁrming the speciﬁcity
of immune response generated from immunization.
We also obtained the same levels of IFN-g secretion to the in-
dividual NYESO and MAGE epitopes when CpG-NYESO-E2 and
CpG-MAGE-E2 nanoparticles were co-administered, relative to
each nanoparticle formulation separately [Fig. 6B]; this shows that
the speciﬁc IFN-g responses to individual epitopes were preserved
after co-immunization. The result is an additive effect to IFN-g
secretion, with the total IFN-g frequencies of group f (sum of
NYESO- and MAGE-speciﬁc IFN-g) being approximately equal to
the sum of individual NYESO-speciﬁc IFN-g (group b) and MAGE-
speciﬁc IFN-g (group d). Furthermore, this additive effect to IFN-g
secretion from the simultaneous immunization is entirely antigen-
speciﬁc and is not due to any adjuvant effect from the CpG-E2
nanoparticle itself, since the addition of CpG-E2 alone did not
promote further speciﬁc IFN-g secretion (compare formulations a
to b, and c to d; Fig. 6B).
Consistent with the ELISpot data, splenocytes isolated frommice
simultaneously immunized with CpG-NYESO-E2 and CpG-MAGE-
E2 nanoparticles (25 mg each, 50 mg total per dose) signiﬁcantly
enhanced the lytic activity toward A375 [Fig. 6C], in a dose
dependent manner [Fig. 6D], relative to unbound CpG, NYESO, and
MAGE epitopes. As expected, the lytic activity was speciﬁc to A375,
with no lysis observed for the control cell line MCF-7 [Fig. 6C].
Furthermore, an elevated and additive lysis activity was observed
for the mice that were co-immunized with CpG-NYESO-E2 and
CpG-MAGE-E2 formulations compared to each formulation sepa-
rately [Fig. 6C].
However, co-immunizationwith higher doses of CpG-NYESO-E2
and CpG-MAGE-E2 nanoparticles (50 mg each,100 mg total per dose)
did not amplify the speciﬁc-IFN-g secretion [Fig. S3] or lysis activity
[Fig. S4], relative to each formulation separately; in fact, both IFN-g
and lysis effects were lower than the effects of each individual
antigen-nanoparticle alone. This observation could be due to T cell
exhaustion [47] or peptide competition on the MHC of the antigen
presenting cells (e.g., DCs) or on the T cell receptors [58,59]. This
data, together with our data for the 100 mg CpG-NYESO-E2 results
[Fig. S1], shows that for our current immunization schedule, the
optimal dose for maximal immunogenic response is 50 mg total
nanoparticle (either 50 mg for one antigen, or 25 mg for two
antigens).
Overall, our results show that co-delivery of a multi-epitope
nanoparticle vaccine can elicit higher cell-mediated immune re-
sponses than single-epitope formulations. Although dosing multi-
ple (unconjugated) peptides in solution has shown to increase
immune responses in the clinic [39e41], and others have investi-
gated alternative classes of antigen combinations [60,61], our study
is the ﬁrst investigation to examine the efﬁcacy of administering
multiple cancer-testis epitopes peptides within the context of
nanoparticles. Our data show that (1) co-immunization of our E2nanoparticle vaccines can preserve the individual cell-mediated
effects against cancer-testis antigens and (2) these IFN-g and lytic
effects are additive.
Vaccination of cytotoxic T-cell epitopes in combination with
helper epitopes have also been investigated by others. While some
studies show this to be a successful strategy [62], other evidence
has demonstrated that the CD8 T cell response can be reduced after
co-immunization with T helper epitopes [62,63]. Thus, using T
helper epitopes within our nanoparticle vaccines could be another
important approach to examine towards increasing efﬁcacy.
4. Conclusion
In this study, we have investigated the effects of incorporating
clinically-relevant human cancer-testis antigens into a nanoparticle
platform that had been previously shown to increase cancer vac-
cine efﬁcacy. We examined whether higher cell-mediated immune
responses can be achieved by simultaneously packaging of CT an-
tigens and CpG adjuvant to the E2 nanoparticle. In a HLA-A2
transgenic mouse model, we found that immunization with
nanoparticle formulations containing CpG and CT antigens resulted
in a signiﬁcantly higher speciﬁc IFN-g frequencies compared to
unbound antigen and CpG. Further, we observed an elevated lysis
activity towards a target cancer cell line (A375). Additionally,
simultaneous delivery of CpG-NYESO-E2 and CpG-MAGE-E2
nanoparticles preserved the effects of the individual antigen-
nanoparticles, and resulted in an additive IFN-g secretion and
lysis activity relative to each separate nanoparticle formulation.
Altogether, this work shows the advantages of using the E2 nano-
particle as an effective vaccine platform to deliver cancer-testis
antigens for higher cell-mediated activation.
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